Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design challenges.
Narcolepsy treatment breakthrough as FDA approves Takeda's oral drug Orzeyful, offering the first therapy to target all type…
Sparsentan shows mixed results in FSGS Phase 3 trial compared to irbesartan, revealing key benefits and trial design…
Sparsentan FSGS treatment offers a new FDA‑approved option for focal segmental glomerulosclerosis, prompting clinicians to compare it with…
Journavx revenue surged as Vertex Pharmaceuticals reported $3.33 billion Q2 earnings, driven by the new acute pain drug’s…
Discover how ALK-positive lung cancer treatment is evolving with new inhibitors, improving survival for thousands of patients worldwide.
Biosimilars reduce drug costs by up to 70%, but patient access depends on insurance coverage and policy decisions.
Discover how obesity medications like semaglutide may help manage metabolic side effects from antipsychotics.
Learn why user access to Yesafili, a biosimilar for eye conditions like wAMD, may be restricted and how…
Zambia's delay in signing a health memorandum with the US stems from disagreements over data and specimen sharing,…
Lenacapavir for HIV PrEP accounted for only 1% of all PrEP in the first six months after FDA…
